Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kristina Rowe

Internal Medicine Havelock, NC Medical Doctor

NPI 1376536151 CMS profile 16343

532 Webb Blvd., Havelock, NC 28532

Open in the dashboard

General payments

$3,466

199 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kristina Rowe of Havelock, NC is reported in the CMS Open Payments database as having received $3,466 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $80 4
2023 General $649 34
2022 General $500 27
2021 General $480 26
2020 General $447 26
2019 General $1,311 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina Rowe
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kristina Rowe were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kristina Rowe Internal Medicine median Middle half National median
2019 $1,311 $159 $48–$570 $163
2020 $447 $119 $33–$402 $114
2021 $480 $135 $37–$521 $132
2022 $500 $141 $42–$496 $149
2023 $649 $149 $45–$519 $160
2024 $80 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amgen Inc. $999 56 payments
  2. AbbVie, Inc. $641 33 payments
  3. Lilly USA, LLC $512 36 payments
  4. Janssen Biotech, Inc. $299 13 payments
  5. Regeneron Healthcare Solutions, Inc. $157 11 payments
  6. Novo Nordisk Inc $122 8 payments
  7. Aurinia Pharma U.S., Inc. $98 7 payments
  8. Celgene Corporation $97 5 payments
  9. Boston Scientific Corporation $72 2 payments
  10. Pfizer Inc. $67 5 payments
  11. Other $403 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,459 198 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2024
  1. Prolia $608 39 payments
  2. TALTZ $472 33 payments
  3. EVENITY $386 28 payments
  4. OLUMIANT $336 23 payments
  5. RINVOQ $281 14 payments
  6. HUMIRA $244 13 payments
  7. SIMPONI ARIA $198 9 payments
  8. Enbrel $179 8 payments
  9. STELARA $164 8 payments
  10. KEVZARA $157 11 payments
  11. Other $2,072 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

3,672

Median for Internal Medicine: 777

Drug cost

$305,774

Median for Internal Medicine: $73,373

Branded share of claims

18.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 76 $115,882
Eliquis Apixaban Brand 47 $44,499
Trulicity Dulaglutide Brand 19 $32,482
Januvia Sitagliptin Phosphate Brand 25 $27,705
Jardiance Empagliflozin Brand 30 $22,766
Atorvastatin Calcium Generic 372 $4,254
Wixela Inhub Fluticasone Propion/Salmeterol Brand 16 $3,582
Duloxetine Hcl Generic 63 $3,344
Diclofenac Sodium Generic 45 $3,017
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $2,885

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$64,790

Of which drugs: $16,032

Medicare patients

315

Average age 76

Services billed

4,422

182 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Arthritis 44%
Ischemic heart disease 24%
Chronic kidney disease 20%
COPD 18%
Atrial fibrillation 17%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 29 29 $8,296
Vaccine for influenza for injection into muscle 90662 Office 21 21 $1,511
Injection, methylprednisolone acetate, 80 mg J1040 Office 23 45 $250
Injection, ketorolac tromethamine, per 15 mg J1885 Office 18 78 $26
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 48 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $29
$29 — —
INJECTAFER
  • Daiichi Sankyo Inc. $22
$22 — —
TALTZ
  • Lilly USA, LLC $7
$7 — —
OLUMIANT
  • Lilly USA, LLC $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record